Ademi LLP has started an investigation into Zoetis for potential securities fraud related to inaccurate statements about its financials, business operations, and prospects. The probe follows Zoetis's admission that customers are cutting back on premium spending for non-emergency pet healthcare. This could impact investor confidence and the company's stock performance. Investors are invited to join the investigation or seek more information at no cost or obligation.
Bernstein Liebhard LLP announced a class action lawsuit against Zoetis Inc. for allegedly making false and misleading statements about its business and financial health between January 14, 2025, and May 6, 2026. The lawsuit claims these misrepresenta...
Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026. The lawsuit alleges that Zoetis made false or misleading statements about the market performance and ado...
A class action lawsuit has been filed against Zoetis Inc. and certain officers, alleging they made false statements about the growth and market share of key products in the Companion Animal segment. The complaint claims Zoetis failed to disclose weak...
Zoetis Inc. is the subject of a class action lawsuit alleging it misled investors about weakening sales of key animal health products, including Librela, Simparica Trio, Apoquel, and Cytopoint. The lawsuit claims Zoetis and its executives failed to d...
A class action lawsuit has been filed against Zoetis Inc. alleging the company misled investors about the strength of its Companion Animal segment. The lawsuit claims Zoetis portrayed this segment as a strong growth driver while hiding safety concern...
